Avacta Group plc is a UK-based clinical-stage biopharmaceutical company focused on developing precision oncology therapies. The company's core technology includes the proprietary pre|CISION platform, a tumor-activated delivery system that releases potent anti-cancer payloads directly within the tumor microenvironment, and the Affimer platform, which utilizes engineered proteins as an alternative to traditional antibodies. Avacta's lead clinical candidate, AVA6000, is a pre|CISION-enabled form of doxorubicin currently in Phase 1 trials for solid tumors. In 2024, the company strategically divested its diagnostics division, which included Launch Diagnostics and Coris BioConcept, to transition entirely into a dedicated therapeutics business. Headquartered in London, Avacta aims to improve healthcare outcomes by addressing the efficacy and safety challenges of conventional cancer treatments.
